These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 3632647)

  • 1. Studies on the pharmacokinetics of hirudin.
    Markwardt F; Nowak G; Stürzebecher U; Walsmann P
    Biomed Biochim Acta; 1987; 46(4):237-44. PubMed ID: 3632647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic studies with recombinant hirudin in dogs.
    Nowak G; Markwardt F; Fink E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological survey of recombinant hirudin.
    Markwardt F; Fink G; Kaiser B; Klöcking HP; Nowak G; Richter M; Stürzebecher J
    Pharmazie; 1988 Mar; 43(3):202-7. PubMed ID: 3380865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.
    Bichler J; Fichtl B; Siebeck M; Fritz H
    Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and anticoagulant effect of hirudin in man.
    Markwardt F; Nowak G; Stürzebecher J; Griessbach U; Walsmann P; Vogel G
    Thromb Haemost; 1984 Oct; 52(2):160-3. PubMed ID: 6523433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
    Boström SL; Hansson GF; Sarich TC; Wolzt M
    Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
    Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
    Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
    Bichler J; Siebeck M; Fichtl B; Fritz H
    Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological studies on the antithrombotic action of hirudin in experimental animals.
    Markwardt F; Hauptmann J; Nowak G; Klessen C; Walsmann P
    Thromb Haemost; 1982 Jun; 47(3):226-9. PubMed ID: 7112494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
    Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
    Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
    Ahr HJ; Boberg M; Brendel E; Krause HP; Steinke W
    Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
    Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
    Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
    Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
    Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tissue residue profiles of erythromycin in broiler chickens after different routes of administration.
    Goudah A; Abo El Sooud K; Abd El-Aty AM
    Dtsch Tierarztl Wochenschr; 2004 Apr; 111(4):162-5. PubMed ID: 15171602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human.
    Timchalk C; Nolan RJ
    Toxicol Appl Pharmacol; 1997 Jun; 144(2):268-78. PubMed ID: 9194410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
    Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
    Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.